INDP
Indaptus Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$138.16M
P/E Ratio
—
EPS
$-12.70
Beta
1.39
52W High
$19.91
52W Low
$0.92
50-Day MA
$2.11
200-Day MA
$2.93
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Indaptus Therapeutics Inc
Indaptus Therapeutics Inc. is an innovative biotechnology company dedicated to developing advanced immunotherapies aimed at revolutionizing cancer treatment. Leveraging its proprietary platform that optimizes the immune system's ability to detect and eradicate tumor cells, Indaptus is committed to enhancing treatment effectiveness and patient outcomes. The firm's diverse pipeline of clinical candidates targets significant unmet needs in oncology, positioning it for strong growth amidst a competitive landscape. With a focus on scientific advancement and collaborations with premier research institutions, Indaptus is well-equipped to become a transformative player in the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.83M |
| Operating Margin | 0.00% |
| Return on Equity | -932.00% |
| Return on Assets | -286.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.01 |
| Price-to-Book | 110.71 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $113.24M |
| Float | $1.18M |
| % Insiders | 0.74% |
| % Institutions | 0.07% |
Historical Volatility
HV 10-Day
132.95%
HV 20-Day
131.17%
HV 30-Day
147.45%
HV 60-Day
126.15%
HV Rank
—
Volatility is currently contracting
More HEALTHCARE Stocks
Data last updated: 5/25/2026